NCT06145412View on ClinicalTrials.gov

A Study of Xevinapant With Cisplatin and Radiation Therapy After Surgery in People With Head and Neck Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

November 16, 2023

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Head and Neck Cancer
Interventions
DRUG

Xevinapan

Xevinapant (oral dose of 200mg per day on days 1-14 every 21 days for 3 cycles)

DRUG

Cisplatin

Cisplatin (2-3 cycles, with 100mg/m2 per cycle q3 weeks)

RADIATION

External beam

60 - 66 Gy in 2 Gy fractions for patients without gross disease and 70 Gy for patients with early recurrence) with concurrent cisplatin (40 mg/m2 once weekly)

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Suffolk - Commack, Commack

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT06145412 - A Study of Xevinapant With Cisplatin and Radiation Therapy After Surgery in People With Head and Neck Cancer | Biotech Hunter | Biotech Hunter